Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxcarbazepine - Novartis

Drug Profile

Oxcarbazepine - Novartis

Alternative Names: GP 47680; KIN-493; NPC 04; Oxacarbazepine; TRI 476; Trileptal

Latest Information Update: 01 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Queen Mary University of London
  • Class Antiepileptic drugs; Dibenzazepines; Mood stabilisers; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Phase II Multiple sclerosis
  • Discontinued Bipolar disorders; Diabetic neuropathies; Neurological disorders

Most Recent Events

  • 01 Jul 2019 Oxcarbazepine is not yet available for Epilepsy in Japan (PO)
  • 31 Jan 2018 Queen Mary University of London completes a phase II trial in Multiple sclerosis in United Kingdom (PO) (NCT02104661)
  • 04 Jul 2016 Registered for Epilepsy in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top